Partner Therapeutics

Partner Therapeutics company information, Employees & Contact Information

WE'RE ALL IN FOR FIGHT AGAINST CANCER Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes. THE PATIENT IS NUMBER ONE We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones. FIGHTING CANCER IS TEAM SPORT We believe that cancer is a complex, dynamic disease that requires a multi-faceted, multi-disciplinary approach to tackle. We believe in teamwork at each stage of a therapy’s development, and seek to build teams of experts, both internally and externally, that cover the breadth and depth of the complex problem that is cancer. We work with leading companies and investigators to ensure that our products are tested in the best settings, and in combination with highest potential regimens to maximize benefit to patients and to advance the understanding of cancer treatment. We seek to engage all members of the cancer treatment team as well as thought-leading physicians and patient advocacy organizations to ensure that clear, complete and balanced information about our products is proactively communicated and readily available. We work to support the extraordinary dedication of the medical teams that represent the front lines in the war on cancer. OUTCOMES ARE OUR YARDSTICK We believe that innovation is not enough. In the challenging world of today’s healthcare climate, we strive to develop and assess our products based on the real-world impact they have in improving the quality and duration of our patients’ lives. We measure our success in the birthdays, anniversaries and other important life moments that our patients are able to enjoy.

Company Details

Employees
190
Founded
-
Address
19 Muzzey St, Lexington,massachusetts 02421,united States
Phone
781-786-2405
Email
me****@****rtx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lexington, Massachusetts
Looking for a particular Partner Therapeutics employee's phone or email?

Partner Therapeutics Questions

News

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC - The AI Journal

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC The AI Journal

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer - Yahoo Finance

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer Yahoo Finance

Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer - PR Newswire

Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer PR Newswire

Merus Partners with PTx for U.S. Rights to Novel Cancer Drug Zeno, FDA Review Underway - Stock Titan

Merus Partners with PTx for U.S. Rights to Novel Cancer Drug Zeno, FDA Review Underway Stock Titan

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease - PR Newswire

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease PR Newswire

Partner Therapeutics, Inc. (PTx) Closes $60 Million Financing - PR Newswire

Partner Therapeutics, Inc. (PTx) Closes $60 Million Financing PR Newswire

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications - PR Newswire

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications PR Newswire

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome - PR Newswire

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome PR Newswire

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function - PR Newswire

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function PR Newswire

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi - PR Newswire

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi PR Newswire

Top Partner Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant